Skip to Main Content (Press Enter)

Logo UNIMORE
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze

UNI-FIND
Logo UNIMORE

|

UNI-FIND

unimore.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Professioni
  • Persone
  • Pubblicazioni
  • Strutture
  • Terza Missione
  • Attività
  • Competenze
  1. Pubblicazioni

The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people

Articolo
Data di Pubblicazione:
2018
Citazione:
The extent of B-cell activation and dysfunction preceding lymphoma development in HIV-positive people / Shepherd, L., Borges, Ã..H., Harvey, R., Bower, M., Grulich, A., Silverberg, M., Weber, J., Ristola, M., Viard, J.-P., Bogner, J.R., Gargalianos-Kakolyris, P., Mussini, C., Mansinho, K., Yust, I., Paduta, D., Jilich, D., Smiatacz, T., Radoi, R., Tomazic, J., Plomgaard, P., et al.. - In: HIV MEDICINE. - ISSN 1464-2662. - 19:2(2018), pp. 90-101. [10.1111/hiv.12546]
Abstract:
Objectives: B-cell dysfunction and activation are thought to contribute to lymphoma development in HIV-positive people; however, the mechanisms are not well understood. We investigated levels of several markers of B-cell dysfunction [free light chain (FLC)-κ, FLC-λ, immunoglobulin G (IgG), IgA, IgM and IgD] prior to lymphoma diagnosis in HIV-positive people. Methods: A nested matched case–control study was carried out within the EuroSIDA cohort, including 73 HIV-positive people with lymphoma and 143 HIV-positive lymphoma-free controls. Markers of B-cell dysfunction were measured in prospectively stored serial plasma samples collected before the diagnosis of lymphoma (or selection date in controls). Marker levels ⠤ 2 and > 2 years prior to diagnosis were investigated. Results: Two-fold higher levels of FLC-κ [odds ratio (OR) 1.84; 95% confidence interval (CI) 1.19, 2.84], FLC-λ (OR 2.15; 95% CI 1.34, 3.46), IgG (OR 3.05; 95% CI 1.41, 6.59) and IgM (OR 1.46; 95% CI 1.01, 2.11) were associated with increased risk of lymphoma > 2 years prior to diagnosis, but not ⠤ 2 years prior. Despite significant associations > 2 years prior to diagnosis, the predictive accuracy of each marker was poor, with FLC-λ emerging as the strongest candidate with a c-statistic of 0.67 (95% CI 0.58, 0.76). Conclusions: FLC-κ, FLC-λ and IgG levels were higher > 2 years before lymphoma diagnosis, suggesting that B-cell dysfunction occurs many years prior to lymphoma development. However, the predictive value of each marker was low and they are unlikely candidates for risk assessment for targeted intervention.
Tipologia CRIS:
Articolo su rivista
Keywords:
B-cell dysfunction; biomarkers; free light chains; HIV; immunoglobulins; lymphoma; Health Policy; Infectious Diseases; Pharmacology (medical)
Elenco autori:
Shepherd, L.; Borges, Ã . H.; Harvey, R.; Bower, M.; Grulich, A.; Silverberg, M.; Weber, J.; Ristola, M.; Viard, J. -P.; Bogner, J. R.; Gargalianos-Kakolyris, P.; Mussini, C.; Mansinho, K.; Yust, I.; Paduta, D.; Jilich, D.; Smiatacz, T.; Radoi, R.; Tomazic, J.; Plomgaard, P.; Frikke-Schmidt, R.; Lundgren, J.; Mocroft, A.; Losso, M.; Kundro, M.; Schmied, B.; Karpov, I.; Vassilenko, A.; Mitsura, V. M.; Paduto, D.; Clumeck, N.; De Wit, S.; Delforge, M.; Florence, E.; Vandekerckhove, L.; Hadziosmanovic, V.; Begovac, J.; Machala, L.; Sedlacek, D.; Kronborg, G.; Benfield, T.; Gerstoft, J.; Katzenstein, T.; Møller, N. F.; Pedersen, C.; Ostergaard, L.; Wiese, L.; Nielsen, L. N.; Zilmer, K.; Jelena, S.; Nakkusosakond, S.; Kohtla-Järve, Null; Ristola, M.; Aho, I.; Girard, P. -M.; Pradier, C.; Fontas, E.; Duvivier, C.; Rockstroh, J.; Schmidt, R.; Degen, O.; Stellbrink, H. J.; Stefan, C.; Fätkenheuer, G.; Chkhartishvili, N.; Gargalianos, P.; Xylomenos, G.; Armenis, K.; Sambatakou, H.; Szlávik, J.; Gottfredsson, M.; Mulcahy, F.; Turner, D.; Burke, M.; Shahar, E.; Hassoun, G.; Elinav, H.; Haouzi, M.; Elbirt, D.; Sthoeger, Z. M.; D'Arminio Monforte, A.; Esposito, R.; Mazeu, I.; Mazzotta, F.; Gabbuti, A.; Vullo, V.; Lichtner, M.; Zaccarelli, M.; Antinori, A.; Acinapura, R.; Plazzi, M.; Lazzarin, A.; Castagna, A.; Gianotti, N.; Galli, M.; Ridolfo, A.; Sacco, Osp. L; Rozentale, B.; Uzdaviniene, V.; Matulionyte, R.; Staub, T.; Hemmer, R.; Reiss, P.; Ormaasen, V.; Maeland, A.; Bruun, J.; Knysz, B.; Gasiorowski, J.; Inglot, M.; Horban, A.; Bakowska, E.; Flisiak, R.; Grzeszczuk, A.; Parczewski, M.; Maciejewska, K.; Aksak-Was, B.; Beniowski, M.; Mularska, E.; Gensing, M.; Jablonowska, E.; Malolepsza, E.; Wojcik, K.; Mozer-Lisewska, I.; Caldeira, L.; Maltez, F.; Oprea, C.; Victor, B.; Panteleev, A.; Panteleev, O.; Yakovlev, A.; Trofimora, T.; Khromova, I.; Kuzovatova, E.; Borodulina, E.; Vdoushkina, E.; Jevtovic, D.; Gatell, J. M.; Miró, J. M.; Moreno, S.; Rodriguez, J. M.; Clotet, B.; Jou, A.; Paredes, R.; Tural, C.; Puig, J.; Bravo, I.; Domingo, P.; Gutierrez, M.; Mateo, G.; Sambeat, M. A.; Laporte, J. M.; Falconer, K.; Thalme, A.; Sonnerborg, A.; Blaxhult, A.; Flamholc, L.; Scherrer, A.; Weber, R.; Cavassini, M.; Calmy, A.; Furrer, H.; Battegay, M.; Schmid, P.; Kuznetsova, A.; Kyselyova, G.; Sluzhynska, M.; Gazzard, B.; Johnson, A. M.; Simons, E.; Edwards, S.; Phillips, A.; Johnson, M. A.; Mocroft, A.; Orkin, C.; Scullard, G.; Clarke, A.; Leen, C.; Gatell, J.; Gazzard, B.; Horban, A.; Karpov, I.; Losso, M.; D'Arminio Monforte, A.; Pedersen, C.; Reiss, P.; Rockstroh, J.; Rockstroh, J.; Kirk, O.; Kirk, O.; Peters, L.; Matthews, C.; Fischer, A. H.; Bojesen, A.; Raben, D.; Kristensen, D.; Grønborg Laut, K.; Larsen, J. F.; Podlekareva, D.; Cozzi-Lepri, A.; Schultze, A.; Amele, S.
Autori di Ateneo:
MUSSINI Cristina
Link alla scheda completa:
https://iris.unimore.it/handle/11380/1155052
Link al Full Text:
https://iris.unimore.it//retrieve/handle/11380/1155052/296847/hiv.12546%20(1).pdf
Pubblicato in:
HIV MEDICINE
Journal
  • Dati Generali

Dati Generali

URL

http://www.wiley.com/bw/journal.asp?ref=1464-2662
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.2.0